Apta-New1

Apta-New1 is an investigational aptamer-drug conjugate (ApDC) developed by Aptabio Therapeutics for the treatment of solid tumors, with a primary focus on liver cancer. It is part of Aptabio's Apta-DC platform, which leverages the high specificity of aptamers—single-stranded oligonucleotides—to deliver cytotoxic agents directly to malignant cells. This targeted approach is designed to enhance therapeutic efficacy while minimizing the systemic side effects typically associated with conventional chemotherapy. While the specific molecular target and payload for Apta-New1 remain undisclosed in current pipeline materials, it represents an expansion of the company's oncology portfolio alongside other candidates that target nucleolin.